Cancer News
Immunotherapy holds promise for ovarian cancer patients
In a trial, immunotherapy kept the cancer away longer in patients with late-stage ovarian cancer, bringing personalized medicine one step closer to reality.
Addition to ovarian cancer standard treatment extends survival
Women receiving bevacizumab in addition to standard chemotherapy for ovarian cancer extended overall survival vs receiving standard chemotherapy treatment alone.
New data on radiation overturns prostate cancer treatment approach
Findings of two clinical trials overturn the widely accepted tactic of delaying radiation treatment to prostate cancer patients in order to reduce side effects.
Conservative treatment: a better option for some prostate cancer patients
Results from a population-based study show favorable survival outcomes among older patients with low-risk prostate cancer treated with conservative management.
Vitamin D as an alternative to surgery/radiation in prostate cancer
Vitamin D can fight inflammation and improve the tumors of prostate cancer patients reducing the need for surgery or radiation, according to scientists.
Yet another reason for prostate cancer patients to quit smoking
Prostate cancer patients who smoke or have quit smoking less than 10 years previously, have twice the risk of a recurrence after surgery, according to new research.
Avoid smoking and alcohol during head/neck cancer treatment
Patients with head and neck cancer undergoing radiotherapy or chemoradiotherapy should avoid current smoking and heavy alcohol consumption, according to a new report.
New treatment for Hodgkin lymphoma doubles progression free survival
The new drug brentuximab vedotin increased progression free survival in adults with hard-to-treat Hodgkin lymphoma treated immediately after stem cell transplant.
Combine immunotherapy and targeted treatment to fight melanoma
Combining immunotherapy and cancer-targeted treatment shows more promising signs of more effectively controlling of advanced melanoma than previous treatments.
Rare blood cancer targeted therapy gets EU approval
Ruxolitinib was approved in EU for the treatment of adult patients of a rare and incurable blood cancer associated with an overproduction of blood cells.
New drug for melanoma available in UK under early access scheme
Cancer drug pembrolizumab was accepted under UK’s early access scheme to treat patients with advanced melanoma. The drug is not yet available in Europe.
Liver-sparing operation: beneficial approach for liver cancer patients
Removing less of the liver during an operation for liver cancer leads to lower mortality and complication rates in liver cancer patients, according to new study.
Low-grade brain tumors respond better to combination therapy
Patients with low-grade glioma, a type of brain cancer, benefited from combining chemotherapy with radiation therapy, new clinical findings suggest.
New drug approval for pediatric neuroblastoma
The FDA has authorized dinutuximab (Unituxin) for the treatment of pediatric patients of high-risk neuroblastoma.
Good news for breast cancer patients who want to get pregnant
Women with breast cancer who receive goserelin had higher pregnancy rates 2 years after treatment, a study shows.
A familial connection between breast and prostate cancer
Having first-degree relatives with a history of prostate cancer increases a woman’s risk of developing breast cancer, according to a new study.
Targeted therapy with sunitinib against advanced thyroid cancer
Patients with advanced thyroid cancer benefited from a targeted therapy with sunitinib, a drug approved for treatment of several other cancers.
Breast cancer survivors may be at risk of thyroid cancer
Breast cancer survivors found to be prone to thyroid cancer, especially within five years of their breast cancer diagnosis according to a new comparative analysis.
Prostate cancer: news on treatment and control options
Numerous latest findings in prostate cancer care were presented at the Genitourinary Cancers Symposium.
New immunotherapy drug for lung cancer gets early FDA approval
The FDA approved the drug Opdivo for the treatment of patients with advanced non-small cell lung cancer with progression on/after platinum-based chemotherapy.
Efficacy of soft-tissue sarcoma treatment confirmed
A large study of Yondelis in soft-tissue sarcoma patients confirms the drug is effective in delaying progression, even more than in clinical trials.
New treatment for cervical cancer recommended in Europe
Bevacizumab (Avastin) has been recommended as a treatment for cervical cancer patients, expanding its current marketing authorization.
An algorithm can improve outcomes in ovarian cancer patients
Introducing the "Anderson Algorithm”, surgeons achieved complete removal of all visible tumors in ovarian cancer patients, resulting in improved survival rates.
Chemotherapy after surgery may help bladder cancer patients
Taking chemotherapy after surgery was found to improve overall survival in bladder cancer patients.
New lung cancer drug gets EU recommendation
Novartis’ treatment for lung cancer, Zykadia, got recommendation for approval from European health regulators.
Breast cancer: avoid mastectomy with pre-surgery chemotherapy
Women with breast cancer may avoid surgical removal of the breast if they undergo chemotherapy before a cancer operation.
Kidney cancer: identical results for common treatment and placebo
Clinical findings indicate that widely used treatments of metastatic kidney cancer, sorafenib and sunitinib, had similar disease recurrence results with placebo.
New blood cancer drug gets FDA approval
Novartis multiple myeloma drug, Farydak received FDA’s approval, in spite of advisory panel’s negative opinion.
Men who have had testicular cancer at higher risk of prostate cancer
A study of 180,000 men indicates that men with history of testicular cancer have much higher risk of prostate cancer.
Perils of active surveillance on intermediate-risk prostate cancer
Men with intermediate-risk prostate cancer under active surveillance had significantly worse outcomes compared to those with low risk, according to a study.